This review summarizes the trajectory and current outcomes of TAVR as a viable treatment option for higher-risk patients with symptomatic severe aortic stenosis.
Reaffirms TAVR as a standard of care for high-risk severe aortic stenosis;.
Transcatheter aortic valve replacement (TAVR) has exploded into medical care for aortic stenosis, thus changing the treatment options for patients. TAVR is currently approved for extreme-risk, high-risk, and intermediate-risk patients with symptomatic severe aortic stenosis, and randomized trials for low-risk patients are underway. This article traces the trajectory of TAVR as a viable option for higher-risk patients and examines current outcomes.
No takes yet. Share an insight, caveat, or question.
Reyes et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: